{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:13:35Z","timestamp":1788779615930,"version":"build-2803163510"},"reference-count":69,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ruth and Fred Kunnes Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Hepatitis B virus (HBV) infection is a worldwide health concern that infects nearly 254 million people globally and causes more than 1 million deaths annually. The highest prevalence is seen in sub-Saharan Africa and the Western Pacific region. Cirrhosis, liver failure, and hepatocellular carcinoma (HCC) are reported as leading complications of chronic HBV. The route of transmission of this infection is mainly by exposure to infected blood and bodily fluids. Transmission from mother-to-child remains the predominant route in highly endemic areas. Vaccination has significantly reduced HBV seroprevalence and complications. However, incomplete vaccination of newborns continues to be a major obstacle to elimination of the disease. Current prevention strategies include universal vaccination, perinatal prophylaxis with hepatitis B immune globulin, and maternal antiviral therapy in pregnant women with high viral load. The management of chronic hepatitis B virus infection predominantly depends on nucleoside analogs, including entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide, as well as pegylated interferon alfa. These therapies effectively suppress viral replication and reduce the risks of cirrhosis, HCC, and liver-related mortality, but they rarely achieve functional cure characterized by hepatitis B surface antigen loss. The persistence of covalently closed circular DNA (cccDNA) remains a major hindrance in HBV eradication. Therefore, novel therapeutic strategies targeting different stages of the viral life cycle, including capsid assembly modulators, small interfering RNAs, nucleic acid polymers, and cccDNA-directed approaches, are under active investigation. This review summarizes the epidemiology, prevention, current therapies, clinical outcomes, and emerging therapeutic advances in HBV infection, highlighting ongoing efforts toward achieving a functional cure and global HBV elimination.<\/jats:p>","DOI":"10.3390\/biom16091290","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:30:46Z","timestamp":1788777046000},"page":"1290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis B Virus: Epidemiology, Prophylaxis, Therapy, Clinical Outcomes, and Novel Therapeutic Directions"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2341-0974","authenticated-orcid":false,"given":"Uzair","family":"Iqbal","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Khalid","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"Yukselten","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2494-9734","authenticated-orcid":false,"given":"Farooq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7895-7026","authenticated-orcid":false,"given":"Haseeb","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur Rehman","family":"Khalid","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8253-530X","authenticated-orcid":false,"given":"Mohamed","family":"Shaltout","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Sutton","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries, World Health Organization."},{"key":"ref_2","unstructured":"Polaris Observatory Collaborators (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study. Lancet Gastroenterol. Hepatol., 8, 879\u2013907."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: Current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","unstructured":"GBD 2019 Hepatitis B Collaborators (2022). Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol., 7, 796\u2013829."},{"key":"ref_5","first-page":"CD015536","article-title":"Entecavir for children and adults with chronic hepatitis B","volume":"2025","author":"Wu","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States","volume":"54","author":"Mast","year":"2005","journal-title":"MMWR Recomm. Rep."},{"key":"ref_7","unstructured":"World Health Organization, and UNICEF (2025). WHO\/UNICEF Estimates of National Immunization Coverage (WUENIC), 2024 Revision, World Health Organization."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: The promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1001\/jama.2026.6070","article-title":"Hepatitis B: A review","volume":"335","author":"Jeng","year":"2026","journal-title":"JAMA"},{"key":"ref_15","unstructured":"Centers for Disease Control and Prevention (2024). Viral Hepatitis Surveillance Report\u2014United States, 2022."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2641857","DOI":"10.1080\/21645515.2026.2641857","article-title":"Global, regional, and national burden of chronic hepatitis B, 1990\u20132021, and projections to 2030: An urgent call for action to achieve hepatitis B elimination goals by 2030","volume":"22","author":"Shen","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Universal hepatitis B vaccination in adults aged 19\u201359 years: Updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1038\/srep27251","article-title":"Factors influencing immunologic response to hepatitis B vaccine in adults","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_22","first-page":"1","article-title":"CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management","volume":"62","author":"Schillie","year":"2013","journal-title":"MMWR Recomm. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/hv.34306","article-title":"Hepatitis B vaccination: Are escape mutant viruses a matter of concern?","volume":"11","author":"Romano","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamapediatrics.2026.1226","article-title":"Impact of removing the universal hepatitis B birth-dose vaccination in the US","volume":"180","author":"Lind","year":"2026","journal-title":"JAMA Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jama.2026.0866","article-title":"US newborn hepatitis B virus vaccination rates","volume":"335","author":"Rothman","year":"2026","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hall, E.W., Gounder, P., Bradley, H., and Nelson, N.P. (2026). Economic impact of delaying the infant hepatitis B vaccination schedule. JAMA Pediatr.","DOI":"10.1001\/jamapediatrics.2026.1221"},{"key":"ref_28","first-page":"229","article-title":"Hepatitis B: Part I. Updates on screening and prevention","volume":"113","author":"Moore","year":"2026","journal-title":"Am. Fam. Physician"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jvh.13036","article-title":"Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: A meta-analysis","volume":"26","author":"Song","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.31559","article-title":"Reproductive health and liver disease: Practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Sarkar","year":"2021","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_32","unstructured":"World Health Organization (2024). Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection, World Health Organization."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(24)02351-1","article-title":"Pregnancy and the liver","volume":"405","author":"Rahim","year":"2025","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Lu, Y., Ye, Q., Xia, Y., Zhou, Y., Yao, Q., and Wei, S. (2011). Should chronic hepatitis B mothers breastfeed? A meta analysis. BMC Public Health, 11.","DOI":"10.1186\/1471-2458-11-502"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD-IDSA practice guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/apt.16828","article-title":"Review article: Hepatitis B\u2014Current and emerging therapies","volume":"55","author":"Yardeni","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chen, M.-B., Wang, H., Zheng, Q.-H., Zheng, X.-W., Fan, J.-N., Ding, Y.-L., and Niu, J.-L. (2019). Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224773"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ke, W., Liu, L., Zhang, C., Ye, X., Gao, Y., Zhou, S., and Yang, Y. (2014). Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098865"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.14309\/ajg.0000000000003881","article-title":"Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naive chronic hepatitis B: A real-world evidence from the Global Alliance for the Study of Hepatitis B Virus","volume":"121","author":"Li","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kim, J., Hur, M.H., Kim, S.U., Kim, J.-W., Sinn, D.H., Lee, H.W., Kim, M.Y., Cheong, J.Y., Jung, Y.J., and Lee, H.A. (2023). Inverse propensity score-weighted analysis of entecavir and tenofovir disoproxil fumarate in patients with chronic hepatitis B: A large-scale multicenter study. Cancers, 15.","DOI":"10.3390\/cancers15112936"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic control of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jvh.13040","article-title":"The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics","volume":"26","author":"Gill","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Marcellin, P., Xie, Q., Paik, S.W., Flisiak, R., Piratvisuth, T., Petersen, J., Asselah, T., Cornberg, M., Ouzan, D., and Foster, G.R. (2020). Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230893"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Huang, Z.-H., Lu, G.-Y., Qiu, L.-X., Zhong, G.-H., Huang, Y., Yao, X.-M., Liu, X.-H., Huang, S.-J., Wu, T., and Yuan, Q. (2022). Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: A network meta-analysis. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09413-7"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(24)00431-X","article-title":"Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): Interim results from a randomised controlled trial","volume":"10","author":"Lim","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2026.03.046","article-title":"144 weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial","volume":"85","author":"Wedemeyer","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1080\/14656566.2022.2144219","article-title":"State-of-the-art and emerging antivirals for chronic hepatitis B infection","volume":"23","author":"Papatheodoridi","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00560-17","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","article-title":"Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): A multicentre, double-blind, active-controlled, randomised, phase 2b trial","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials","volume":"79","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","article-title":"Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo","volume":"30","author":"Gorsuch","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhuang, A.-Q., Chen, Y., Chen, S.-M., Liu, W.-C., Li, Y., Zhang, W.-J., and Wu, Y.-H. (2023). Current status and challenges in anti-hepatitis B virus agents based on inactivation\/inhibition or elimination of hepatitis B virus covalently closed circular DNA. Viruses, 15.","DOI":"10.3390\/v15122315"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2023.07.003","article-title":"Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice","volume":"79","author":"Lempp","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/9\/1290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:01:17Z","timestamp":1788778877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/9\/1290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["biom16091290"],"URL":"https:\/\/doi.org\/10.3390\/biom16091290","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}